CPRX (STOCKS)
Catalyst Pharmaceutical Inc.
$23.930000
-0.340000 (-1.40%)
Prev close: $24.270000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Richard John Daly
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,942.51M
- Employees
- 167
- P/E (TTM)
- 14.16
- P/B (TTM)
- 3.25
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $578.20M |
| Benefits Costs and Expenses | $292.40M |
| Cost Of Revenue | $82.82M |
| Costs And Expenses | $292.40M |
| Gross Profit | $495.37M |
| Operating Expenses | $199.22M |
| Selling, General, and Administrative Expenses | $184.52M |
| Research and Development | $14.70M |
| Operating Income/Loss | $258.78M |
| Income/Loss From Continuing Operations After Tax | $217.56M |
| Income/Loss From Continuing Operations Before Tax | $285.80M |
| Income Tax Expense/Benefit | $68.23M |
| Net Income/Loss | $217.56M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $217.56M |
| Net Income/Loss Available To Common Stockholders, Basic | $217.56M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.79 |
| Diluted Earnings Per Share | $1.72 |
| Basic Average Shares | 366,718,027 |
| Diluted Average Shares | 382,015,225 |
| Assets | $1.05B |
| Current Assets | $852.45M |
| Inventory | $28.03M |
| Other Current Assets | $824.42M |
| Noncurrent Assets | $199.15M |
| Fixed Assets | $1.08M |
| Other Non-current Assets | $198.07M |
| Liabilities | $131.36M |
| Current Liabilities | $128.74M |
| Accounts Payable | $9.10M |
| Wages | $10.57M |
| Other Current Liabilities | $109.07M |
| Noncurrent Liabilities | $2.62M |
| Equity | $920.25M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $920.25M |
| Liabilities And Equity | $1.05B |
| Net Cash Flow From Operating Activities | $234.66M |
| Net Cash Flow From Operating Activities, Continuing | $234.66M |
| Net Cash Flow From Investing Activities | -$114.00K |
| Net Cash Flow From Investing Activities, Continuing | -$114.00K |
| Net Cash Flow From Financing Activities | $13.02M |
| Net Cash Flow From Financing Activities, Continuing | $13.02M |
| Net Cash Flow | $247.56M |
| Net Cash Flow, Continuing | $247.56M |
| Comprehensive Income/Loss | $217.56M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $217.56M |
| Other Comprehensive Income/Loss | $0.00 |